Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 2;10(5):ofad217.
doi: 10.1093/ofid/ofad217. eCollection 2023 May.

Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine

Isabelle de Malliard  1 , Anne-Laure Houist  1 , Gilles Peytavin  2   3 , Thomas L'Yavanc  4 , Magali Bouvier  5 , Pierre Cappy  5 , Jean-Daniel Lelièvre  1   6 , Elsa Feredj  1 , William Vindrios  1 , Sebastien Gallien  1 , Giovanna Melica  1
Affiliations

Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine

Isabelle de Malliard et al. Open Forum Infect Dis. .

Abstract

Intramuscular long-acting antiretroviral drugs can improve adherence to lifelong antiretroviral treatment. Nevertheless, adipose tissue thickness and distribution play a critical role with injectable drugs. We describe a virological failure with cabotegravir and rilpivirine in a Black African woman with human immunodeficiency virus type 1 with gynoid fat distribution (ie, adipose tissue prevailing in the pelvis and hip area) and body mass index <30 kg/m2.

Keywords: HIV infection; adipocyte trapping; gynecoid fat distribution; intramuscular long-acting antiretroviral drugs; virological failure.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No potential conflicts.

References

    1. Ryom L, Cotter A, De Miguel R, et al. . 2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0. HIV Med 2020; 21:617–24. - PMC - PubMed
    1. Orkin C, Arasteh K, Hernáandez-Mora MG, et al. . Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med 2020; 382:1124–35. - PubMed
    1. Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. . Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020; 382:1112–23. - PubMed
    1. Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 2021; 60:835–3. - PMC - PubMed
    1. US Food and Drug Administration. FDA approves Cabenuva and Vocabria for the treatment of HIV-1 infection . 2021. Available at: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-.... Accessed 19 November 2022.

LinkOut - more resources